Adomeglivant is primarily researched for its potential therapeutic applications in metabolic disorders, particularly those related to lipid metabolism and insulin resistance. It acts as a modulator of specific pathways involved in glucose and lipid homeostasis, making it a candidate for treating conditions like type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). In preclinical studies, it has shown promise in improving insulin sensitivity and reducing hepatic fat accumulation, which could benefit patients with metabolic syndrome. Additionally, its mechanism of action may offer advantages in managing cardiovascular risk factors associated with metabolic disorders. Ongoing research aims to further explore its efficacy and safety in clinical settings.